MIMEDX Celebrates 15 Year Anniversary of EPIFIX® and AMNIOFIX®
MIMEDX (Nasdaq: MDXG) is marking the 15th anniversary of its placental allografts EPIFIX and AMNIOFIX, used in wound care and surgical recovery.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
MIMEDX (Nasdaq: MDXG) is marking the 15th anniversary of its placental allografts EPIFIX and AMNIOFIX, used in wound care and surgical recovery. Together they appear in nearly 100 clinical and scientific publications, including seven randomized controlled trials, and are described as the industry’s most studied placental allografts.
The company highlighted broad clinical use across more than a dozen surgical specialties and credited employees for advancing its products and peer-reviewed evidence base.
Details
News Market Reaction – MDXG
On Feb 2, the day this news came out, MDXG closed 0.39% below the previous close.
Data tracked by StockTitan Argus for the Feb 2 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Industry’s Most Studied Placental Allografts Appear in Nearly 100 Clinical and Scientific Publications
MARIETTA, Ga., Feb. 02, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the 15th anniversary of EPIFIX and AMNIOFIX, the Company’s placental allografts used in wound care and surgical recovery settings.
“We are thrilled to mark the 15th anniversary of our flagship Wound and Surgical products, EPIFIX and AMNIOFIX, which have been instrumental to our pioneering innovation in the space,” stated Randall Spencer, MIMEDX Vice President, Clinical Innovation. “Over the years, MIMEDX has changed the paradigm of wound care treatment and surgical recovery. The Company’s products have become the placental allografts of choice across many specialties, including in over a dozen surgical fields, for their vast utility, handling characteristics, and robust peer-reviewed data. Together, EPIFIX and AMNIOFIX have been studied in almost 100 clinical and scientific publications which include seven randomized controlled trials, achieving recognition as the industry’s most studied placental allografts. We are grateful to all our dedicated employees who have made it possible for us to reach this milestone.”
About MIMEDX
MIMEDX is a pioneer and leader focused on helping humans heal. With over a decade and a half of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX provides a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.
Contact:
Matt Notarianni
Investor Relations
470-304-7291
mnotarianni@mimedx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.